Results

Most recent

Diabetic Retinopathy

1–4 of 4 results for APX3330

ZETA-1 Phase 2 Trial Safety and Tolerability Results for APX3330 a New Oral Ref-1 Inhibitor for the Treatment of Diabetic Retinopathy
Daniel Su, MD
Annual Meeting Talks
2023
ZETA-1 Phase 2 Trial Efficacy Results for APX3330 a Novel Oral Ref-1 Inhibitor for the Treatment of Diabetic Retinopathy
David R Lally, MD
Annual Meeting Talks
2023
Masked Safety Data from ZETA-1, an Ongoing 24-Week Phase 2 Clinical Trial of APX3330, an Oral Therapeutic Being Developed for the Treatment of Diabetic Retinopathy
Michael J Allingham, MD, PhD
Annual Meeting Talks
2022
APX3330, an Oral Drug in Trial for DR and DME, Demonstrated a Favorable Safety and Tolerability Profile in Multiple Phase 1 and 2 Studies
Michael J Allingham, MD, PhD
Annual Meeting Talks
2021